Placebo to tiotropium
Sponsors
Novartis Pharmaceuticals, Boehringer Ingelheim
Conditions
COPDChronic Obstructive Pulmonary DiseaseChronic Obstructive Pulmonary Disease (COPD)Pulmonary Disease, Chronic Obstructive
Phase 3
A Study to Compare the Lung Effect of Indacaterol and Tiotropium in Chronic Obstructive Pulmonary Disease (COPD)
CompletedNCT00900731
Start: 2009-06-30End: 2010-03-31Updated: 2011-08-19
The Effect of QVA149 on Patient Reported Dyspnea in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
CompletedNCT01490125
Start: 2011-10-31End: 2012-08-31Updated: 2013-12-24
The Effect of QVA149 on Health Related Quality of Life in Patients With Chronic Obstructive Pulmonary Disease (COPD)
CompletedNCT01574651
Start: 2012-05-31End: 2013-04-30Updated: 2014-05-22
Efficacy, Safety, and Tolerability of NVA237 Compared to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD)
CompletedNCT01613326
Start: 2012-06-30End: 2013-01-31Updated: 2014-04-23
Tiotropium Inhalation Capsules and Salmeterol Inhalation Aerosol on Muscular Efficiency and Resting Energy Expenditure (REE) in Patients With Stable Chronic Obstructive Pulmonary Disease (COPD)
CompletedNCT02172794
Start: 2002-05-31Updated: 2018-08-31
Phase 4
Comparison of Indacaterol With That of Placebo in 'Maintenance naïve' Patients With COPD Using Blinded Tiotropium as Active Control
WithdrawnNCT01715311
Start: 2012-11-30End: 2013-09-30Updated: 2017-04-20
Efficacy of NVA237 Compared to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD)
CompletedNCT01922271
Start: 2013-08-31End: 2014-01-31Updated: 2015-01-01
Effect of Glycopyrronium on Morning Symptoms and Pulmonary Function in Patients With Moderate to Severe COPD
CompletedNCT01959516
Start: 2014-02-28End: 2014-10-31Updated: 2016-04-15